Bremelanotide

From Retapedia, the free peptide encyclopedia
Medical disclaimer. This article is for informational purposes only and does not constitute medical advice. Consult a qualified clinician before considering any compound discussed below. See Retapedia : Medical disclaimer.

Bremelanotide is a therapeutically researched peptide studied for its effects on sexual health, injectable, subcutaneous. Bremelanotide (Vyleesi) is an FDA-approved melanocortin agonist for low sexual desire in premenopausal women; preclinical potential for erectile dysfunction.

Bremelanotide, sold under the brand name Vyleesi, is a medication used to treat low sexual desire in women. Specifically it is used for low sexual desire which occurs before menopause and is not due to medical problems, psychiatric problems, or problems within the relationship. It is given by an injection just under the skin of the thigh or abdomen.

Natty status
Bremelanotide is generally regarded as compatible with natural bodybuilding, though competitive federations may differ. See § Natty status.
Contents [hide]
  1. 1 Mechanism of action
  2. 2 Reported effects
  3. 3 Natty status
  4. 4 Research
  5. 5 Related compounds
  6. 6 References
  7. 7 External links

Mechanism of action

FDA-approved (as Vyleesi) for low sexual desire in premenopausal women. Activates central melanocortin receptors to drive arousal. Shows preclinical promise for erectile dysfunction. Given by subcutaneous injection.

Reported effects

Effects reported in the literature and from preclinical models include:

  • PT-141 shows efficacy in erectile dysfunction through central nervous system activation and nitric oxide regulation. [1] Preclinical
  • PT-141 acts on erectile function through a mechanism distinct from that of PDE5 inhibitors. [1] Preclinical
  • A narrative review lists PT-141 among intravenous peptide and amino acid options examined for erectile dysfunction, alongside PnPP-19, L-arginine, and L-citrulline. [1] Preclinical

Evidence grades: FDA approvedApproved (non-US)Phase IIIPhase IIPhase IPreclinicalAnecdotal

Natty status

See also: Peptide § Natty status

Bremelanotide is generally regarded as compatible with the natty designation, particularly when used for therapeutic healing purposes. Opinions vary across natural bodybuilding federations, and athletes who compete should consult the rulebook of their respective sanctioning body.[2]

Research

The peptide has been the subject of 3 studies and reference works collected on this site. Additional bibliography is in § External links below.

Other peptides in this catalogue with overlapping mechanisms or status:

Melanotan II Not natty
Stimulates melanin production to darken skin and facilitate tanning. May also increase sexual arousal and reduce appetite. Unapproved for human use; linked to nausea and mole changes.
Thymosin α-1 Natty
Sharpens adaptive immunity by driving T-cell maturation and dendritic cell activity. Approved abroad as Zadaxin for chronic hepatitis B and as a vaccine adjuvant. Subcutaneous injection.
Delta-sleep-inducing peptide Not natty
A neuropeptide named for inducing delta EEG sleep activity in animals, though its own link to human sleep is weak and poorly characterized. Shows preclinical antiepileptic activity.
Epithalon Not natty
Marketed as an anti-aging peptide. In preclinical studies it boosts telomerase activity, supports the body's own melatonin production, and shows antioxidant effects. Human evidence is minimal.

References

  1. a b c Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions. Recent review
  2. a b World Anti-Doping Agency. (2026). Prohibited List 2026.

External links

Categories: Peptides | Therapeutic peptides | Sexual health | Injectable | Subcutaneous

This page was last updated on August 4, 2026, at 00:41 (UTC).

Research last reviewed on August 4, 2026.

Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply.